Table 4. IFN-γ responses to mycobacterial antigens, PPD and PHA assessed by short or prolonged incubation-based assays.

Patients	Median IFN-γ release in UI/mL (range)		P value
	Incubation time 18 h	Incubation time 6 days
Group A (n = 8)
rESAT-6/rCFP-10	0 (0–0,83)	0,015 (0–0,19)	0,625
PPD	0,865 (0–8,3)	7,2 (0,04–8,29)	0,033
PHA	2,65 (0,21–8,25)	8,55 (2.19–16,93)	0,6
Group B (n = 10)
rESAT-6/rCFP-10	2,5 (0,02–7)	6,69 (2,17–17,95)	0,004
PPD	5,16 (0,43–18,21)	8,44 (5,19–18,55)	0,005
PHA	7,39 (1,16–19,76)	9,19 (1,08–20,1)	0,5
Healthy controls (n = 5)
rESAT-6/rCFP-10	0 (0–0,36)	0 (0–0,05)	0,211
PPD	0,15 (0,1–0,44)	0,29 (0,15–0,51)	0,078
PHA	6,05 (1,05–8,05)	8,27 (0,3–8,89)	0,5

Abbreviations:

PPD: purified protein derivative; PHA: phytohemagglutinin; rESAT-6: recombinant ESAT-6; rCFP-10: recombinant CFP-10.

Group A: TB patients who had a QFT-G reversion (positive to negative) at the end of therapy.

Group B: TB patients who remained QFT-G positive at the end of therapy.